Business Context and Reporting Period
Silexion Therapeutics Corp (SLXN) is a clinical-stage, oncology-focused biotechnology company incorporated in the Cayman Islands with principal operations in Israel. The company develops proprietary RNA-interference (RNAi) therapeutics to silence the KRAS oncogene, primarily targeting locally advanced pancreatic cancer (LAPC). Its lead product candidate, SIL204, is a second-generation siRNA solution designed for intratumoral administration.
This Form 10-K covers the fiscal year ended December 31, 2024. The reporting period includes the consummation of a Business Combination with Moringa Acquisition Corp on August 15, 2024, which resulted in the company becoming a publicly traded entity on the Nasdaq Global Market. The financial statements reflect the operations of the predecessor entity (Silexion Therapeutics Ltd.) prior to the combination and the combined entity thereafter.
Key Financial Metrics
| Metric | 2024 (in thousands) | 2023 (in thousands) |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(16,519) | $(5,108) |
| Operating Expenses | $12,571 | $4,681 |
| Research & Development | $5,815 | $3,708 |
| General & Administrative | $6,756 | $973 |
| Cash and Cash Equivalents (Year End) | $1,187 | $4,595 |
| Accumulated Deficit | $(43,254) | $(26,811) |
| Debt / Convertible Notes | $3,965 (Fair Value) | $0 |
Note: The company has never generated revenue from product sales. Financial expenses in 2024 included a significant non-cash loss of $4.78 million related to the Business Combination transaction.
Material Changes vs. Prior Period
- Net Loss Expansion: Net loss increased by approximately 223% to $16.5 million in 2024 from $5.1 million in 2023. This was driven by increased operating expenses and one-time transaction costs.
- Operating Expenses: Total operating expenses rose by 169% ($7.9 million increase).
- R&D: Increased by 57% primarily due to $2.4 million in share-based compensation and increased payroll following the Business Combination.
- G&A: Increased by 593% to $6.8 million, largely due to $3.4 million in share-based compensation and $1.2 million in professional services related to the SPAC merger and public company compliance.
- Liquidity: Cash and cash equivalents decreased by $3.4 million to $1.2 million, reflecting higher operating burn rates and transaction costs, partially offset by financing activities.
- Capital Structure: The company completed a reverse share split (1-for-9) in November 2024. It also entered into an Equity Line of Credit (ELOC) agreement and issued promissory notes to the SPAC sponsor and underwriters.
Guidance, Outlook, and Risks
Outlook and Management Commentary
Management plans to initiate toxicology studies for SIL204 in 2025, with a regulatory submission targeted for Q1 2026 to initiate a Phase 2/3 clinical trial in the first half of 2026. The company expects to apply for Orphan Drug Designation in the U.S. and EU in 2026.
Subsequent to the reporting period (January 2025), the company raised approximately $5.0 million via a public offering and an additional $3.3 million through an induced warrant exercise transaction.
Material Risks and Contingencies
- Going Concern: The independent auditors have expressed substantial doubt about the company's ability to continue as a going concern. As of December 31, 2024, cash balances were insufficient to fund operations for the next 12 months without additional financing.
- Capital Requirements: The company requires substantial additional funding to advance clinical trials and operations. Failure to secure financing could force a curtailment of operations.
- Nasdaq Compliance: The company received notice of non-compliance with Nasdaq listing rules regarding Market Value of Listed Securities (MVLS) and Market Value of Publicly Held Shares (MVPHS). It has until May 19, 2025, to regain compliance or risk delisting.
- Geopolitical Risk: Operations are centered in Israel. Ongoing conflicts in the Middle East pose risks to operations, employee safety, and capital raising.
- Development Risk: The RNAi therapeutic approach for oncology is unproven. There is no assurance that SIL204 will receive regulatory approval or achieve commercial success.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of cash raised in January 2025 ($8.3 million total) against current burn rates to assess the timeline for the next capital raise.
- Nasdaq Status: Monitor the company's progress in meeting the $50 million MVLS and $15 million MVPHS thresholds by the May 2025 deadline to avoid delisting.
- Dilution Exposure: Review the terms of the ELOC (up to $15 million available), the Sponsor Promissory Note ($3.4 million convertible), and outstanding warrants to understand potential future dilution.
- Clinical Timeline: Confirm the initiation of toxicology studies in 2025 as a critical milestone for the planned 2026 Phase 2/3 trial.
- Going Concern Mitigation: Assess the likelihood of securing additional equity or debt financing given the current market environment and the company's pre-revenue status.